- Home
- About mondoBIOTECH
- Company Overview
- Global Offices
- mondoNEWS
- mondoEVENTS
- mondoPRESS
- Management
- Board of Directors
- Milestones
- Investors
- Business Partners
- Pipeline
- Community
- Careers
- Contact Us
Search
|
|
2010
|
| July 23, 2010 |
| mondoBIOTECH holding AG (SIX:RARE): Board of Directors sets the global terms of a planned capital increase |
| NOT FOR DISTRIBUTION IN THE UNITED STATES (OR TO US CITIZENS), THE UNITED KINGDOM AND THE EEA. |
| July 05, 2010 |
| mondoBIOTECH holding AG (SIX:RARE): path to growth |
| Stans, 5th July 2010 - mondoBIOTECH is approaching the 10th anniversary since its inception and the Company has proved that pure laboratory research is not the only method that allows the discovery of cures for diseases. In todays’ world of segmented know-how and distributed communities of scientists, physicians, patients and others involved in the field, the Search&Match approach that it is at the base of the mondoBIOTECH model is providing a fantastic tool for identifying cures and viable treatments for rare diseases. |
| April 30, 2010 |
| Results of the Annual General Meeting of mondoBIOTECH holding AG (SIX: RARE) |
| Stans, Switzerland – April 30, 2010 - At the Annual General Meeting on April 30, 2010, mondoBIOTECH Holding AG Shareholders unanimously approved the annual report and the group financial statements 2009, agreed with 99.99% of the voting rights to offset the loss for the year against reserves and the further proposed transfer form general to free reserves, discharged with 96.8% of the voting rights the member of the Board of Directors and the Group Executive Committee for 2009, reaffirmed with 99.99% of the voting rights PricewaterhouseCoopers as auditor and approved with 99.99% of the voting rights the amendment of the article 3a of the articles of incorporation inherent the extension of the authorization to issue new shares out of authorized share capital from currently 20 February 2011 to 30 April 2012 while leaving the number of authorized new shares unchanged. 73% of the voting rights were represented at the meeting. |
| April 26, 2010 |
| mondoBIOTECH holding AG (SIX:RARE): board member Michael A. Keller elected a fellow at the American Academy of Arts and Sciences |
| Stans/Palo Alto, 26th April 2010 - Board member Michael A. Keller, Stanford University Librarian, Publisher, and Director Academic Computing as well as a prominent innovator and exploiter of Internet and World Wide Web technologies, has been elected a Fellow of the American Academy of Arts and Sciences. |
| April 21, 2010 |
| mondoBIOTECH holding AG (SIX: RARE): Exclusive engagement with financial services firm WR Hambrecht + Co., LLC |
| Stans, April 21, 2010 - mondoBIOTECH holding AG (SIX: RARE) announces exclusive engagement with prominent Silicon Valley financial services firm WR Hambrecht + Co. |
| April 15, 2010 |
| mondoBIOTECH holding AG (SIX:RARE) hosts “Open Door Days” on 21st and 27th April, 2010. |
| Stans/Palo Alto, April 15, 2010 – mondoBIOTECH holding AG (SIX:RARE) announces today that it will host “Open Door Days” on 21st and 27th April 2010 at 11am CET. All stakeholders who wish to be informed on the business and activities directly from mondoBIOTECH holding AG’s management are invited to attend. |
| April 01, 2010 |
| mondoBIOTECH holding AG (SIX: RARE) published today the invitation to the 3rd Annual General Meeting |
| Stans, Switzerland - April 1, 2010 – The invitation (agenda and proposals of the board of directors) to the 3rd Annual General Meeting is available under www.mondobiotech.com/Investors/General_Meeting.cfm |
| March 31, 2010 |
| mondoBIOTECH holding AG (SIX: RARE): Results 2009 |
| Stans, 31 March 2010. mondoBIOTECH holding AG (SIX: RARE) announces today its financial results 2009. |
| March 30, 2010 |
| mondoBIOTECH holding AG (SIX: RARE) nominates new Board Members for election in its Board of Directors |
| Stans/Palo Alto - March 30, 2010 - At the meeting of 30th March 2010, the Board of Directors of mondoBIOTECH holding AG (SIX: RARE) nominates Prof. Geoffrey West, Prof. Roland M. du Bois, Robert E. Patterson and Mr. Graf Francis von Seilern-Aspang for election as new members of the Board. The election will be discussed and decided at the General Assembly of mondoBIOTECH holding AG scheduled on 30th April 2010. |
| February 18, 2010 |
| mondoBIOTECH holding AG (SIX: RARE) announces today the completion of its capital increase |
| Stans, Switzerland - February 18, 2010 – mondoBIOTECH holding AG (SIX: RARE) announces today the closing of its capital increase. The Company has raised CHF 9.2 million. Assuming execution, the options are expected to generate an additional contribution of gross CHF 1.7 million within the next three years. The expected placement of the newly offered shares and options with Imperial Fund Ltd. as a result of its pre-commitment as communicated by mondoBIOTECH has been completed in the measure of31%. In aggregate, subscriptions for 79'134 new shares and 11'141 options equal to 26% of the offered shares and 4% of the offered options have been received in the Offering. Given the difficult economic environment, the Company considers the outcome of the Offering as positive. The Company's Board of Directors has decided to proceed with the Offering as planned. Therefore, the first trading day of the newly issued shares is expected to be February, 19 2010 and delivery of the newly issued shares and options is expected to occur on February 22, 2010. |
| February 03, 2010 |
| Lung Rx LLC, a subsidiary of United Therapeutics Corporation (NASDAQ: UTHR), and mondoBIOTECH holding AG (SIX: RARE) announce today a global strategic partnership agreement for the development of Aviptadil platform. |
| Silver Spring/Stans - February 3, 2010 – After completion by Mondobiotech of a Phase II study where inhaled Aviptadil was shown to have a unique safety profile and promising signals of long term efficacy over currently approved therapies in patients affected by Pulmonary Arterial Hypertension (PAH), United Therapeutics Corporation’s Lung Rx subsidiary and Mondobiotech finalized a global strategic partnership focused on the development of Aviptadil for a range of indications, as for example PAH, Sarcoidosis, Idiopathic Pulmonary Fibrosis (IPF) and Acute Respiratory Distress Syndrome (ARDS). The platform can generate more than 1 billion CHF turnover. United Therapeutics, a successful biotech company, listed at the NASDAQ with a capitalization of over 3 billion USD, and specialized in finding and developing therapies for PAH and other pulmonary diseases with 2 PAH products already on the market, will be responsible for further development and commercialization of the Aviptadil platform. |
| January 27, 2010 |
| mondoBIOTECH Holding AG (SIX: RARE) today announces the first medical product candidate against Extensively Drug-Resistant Tuberculosis (XDR-TB) |
| Stans, Switzerland - January 27, 2010 mondoBIOTECH’s research Community successfully contributes to the global fight against Extensively Drug-Resistant Tuberculosis (XDR-TB). Our mondoBIOTECH Search&Match Internet Laboratory team discovered promising medical product candidates for patients affected by this severe rare disease. Among these candidates, further in vitro examinations confirmed for the first medical product candidate the initial discovery of the mondoBIOTECH Search & Match Internet Laboratory. |
| January 25, 2010 |
| mondoBIOTECH holding AG: the Board of Directors has set the final terms of its planned capital increase |
| NOT FOR DISTRIBUTION IN THE UNITED STATES (OR TO US CITIZENS), THE UNITED KINGDOM AND THE EEA. |
| January 25, 2010 |
| mondoBIOTECH holding AG: interim financial results for Q3 2009 |
| Stans, Switzerland - January 25, 2010 - mondoBIOTECH holding AG (SIX Swiss Exchange: RARE) is publishing today its unaudited interim financial results for Q3 2009 which will be part of the offering circular which is being published tomorrow, 26 February 2009. The Company realized revenues of CHF 12.17 million in the nine months ended 30 September 2009, mainly resulting from services delivered to third parties as well as some outlicencing fees. This is an increase of +11% in comparison to CHF 10.97 million during the same period in 2008. The overall result of the period was a loss of CHF 7.43 million which is a slight increase of the deficit by 4% when compared to the loss of CHF 7.12 million during the same period in 2008. You can download the unaudited interim financial information of mondoBIOTECH holding AG under: mondoBIOTECH holding AG – Interim financial information 30 September 2009 (unaudited) |
| January 15, 2010 |
| mondoBIOTECH holding AG: the extraordinary shareholders' meeting approves all of the Board of Directors’ proposals |
| Stans, Switzerland - January 15, 2010. The shareholders of mondoBIOTECH holding AG have unanimously approved two amendments to the Company's articles of incorporation at today's extraordinary shareholders' meeting, one relating to the usage of conditional share capital, and the other required due to the entry into force of the new Intermediated Security Act. |
| January 14, 2010 |
| Mondobiotech is inventions patent champion in 2009 |
| Stans, Switzerland - January 14, 2010 - mondoBIOTECH holding AG (SIX: RARE), the Swiss biotech company finding therapies for rare diseases announced today a global top ranking position in patent inventions for the year 2009. A report by Thompson Reuters, which highlights twelve key technology areas in 2009 as well as the level of global innovation in each technology, was published by BusinessWeek http://www.businessweek.com on 10th January 2010. BusinessWeek there classifies Mondobiotech as the winner in the category pharmaceutical industry. |
| January 14, 2010 |
| mondoBIOTECH holding AG announces today the terms of its planned share capital increase |
| NOT FOR DISTRIBUTION IN THE UNITED STATES (OR TO US CITIZENS), THE UNITED KINGDOM AND THE REPUBLIC OF ITALY. |
